Please login to the form below

Not currently logged in
Email:
Password:

evolocumab

This page shows the latest evolocumab news and features for those working in and with pharma, biotech and healthcare.

Regeneron’s Dupixent and Praluent fall short

Regeneron’s Dupixent and Praluent fall short

Earlier this week, Sanofi and Regeneron agreed a deal with Express Scripts to discount Praluent in return for a preferred formulary position versus Amgen’s rival drug Repatha (evolocumab).

Latest news

More from news
Approximately 11 fully matching, plus 48 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Apex.co.uk Conferences, Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading event and exhibition agencies, specialising in healthcare. We understand your communication goals, whether...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics